Japanese Researchers Study Substance For Multi-Strain Flu Fight
This article was originally published in PharmAsia News
Executive Summary
Researchers at a Japan institute developed what they believe could protect against many strains of influenza virus by targeting infected cells. Researchers at the National Institute of Infectious Diseases, NOF say they developed a substance that works by concentrating on the infected cells instead of providing immunity. Immunity is lost when a cell mutates, and the researchers are studying whether their substance can fight the H5N1 virus despite its constant mutations. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.